NEA Management Company
Latest statistics and disclosures from NEA Management Company's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ACLX, CELC, Spyglass Pharma, TRVI, SVRA, and represent 62.16% of NEA Management Company's stock portfolio.
- Added to shares of these 3 stocks: Spyglass Pharma (+$192M), ZBIO (+$9.8M), KRRO.
- Started 1 new stock position in Spyglass Pharma.
- Reduced shares in these 4 stocks: RYTM (-$312M), CELC (-$143M), GOSS (-$5.6M), SYBX.
- Sold out of its positions in RYTM, SYBX.
- NEA Management Company was a net seller of stock by $-259M.
- NEA Management Company has $1.8B in assets under management (AUM), dropping by -10.30%.
- Central Index Key (CIK): 0001512848
Tip: Access up to 7 years of quarterly data
Positions held by NEA Management Company consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for NEA Management Company
NEA Management Company holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Arcellx Common Stock (ACLX) | 19.9 | $350M | 3.0M | 114.82 |
|
|
| Celcuity (CELC) | 14.8 | $261M | -35% | 2.3M | 114.14 |
|
| Spyglass Pharma Com Shs | 10.9 | $192M | NEW | 7.4M | 25.91 |
|
| Trevi Therapeutics (TRVI) | 9.0 | $158M | 13M | 11.93 |
|
|
| Savara (SVRA) | 7.6 | $134M | 25M | 5.46 |
|
|
| Monte Rosa Therapeutics (GLUE) | 7.2 | $127M | 7.7M | 16.45 |
|
|
| Mbx Biosciences (MBX) | 6.1 | $108M | 3.6M | 29.85 |
|
|
| Zenas Biopharma (ZBIO) | 4.5 | $79M | +14% | 4.0M | 19.55 |
|
| Coursera (COUR) | 4.3 | $75M | 13M | 5.82 |
|
|
| Aurinia Pharmaceuticals (AUPH) | 3.3 | $59M | 4.0M | 14.82 |
|
|
| Oric Pharmaceuticals (ORIC) | 3.0 | $52M | 4.1M | 12.67 |
|
|
| CRISPR Therapeutics Namen Akt (CRSP) | 2.9 | $50M | 1.1M | 47.57 |
|
|
| Phathom Pharmaceuticals (PHAT) | 1.2 | $22M | 2.0M | 11.11 |
|
|
| CVRX (CVRX) | 1.1 | $19M | 2.0M | 9.46 |
|
|
| Korro Bio (KRRO) | 0.8 | $15M | +18% | 1.3M | 11.32 |
|
| X4 Pharmaceuticals | 0.8 | $13M | 3.2M | 4.13 |
|
|
| Champions Oncology Com New (CSBR) | 0.6 | $9.9M | 1.7M | 5.75 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.5 | $9.5M | 4.4M | 2.13 |
|
|
| Inventiva SA Ads (IVA) | 0.5 | $8.0M | 1.5M | 5.49 |
|
|
| Nkarta (NKTX) | 0.4 | $7.5M | 3.6M | 2.11 |
|
|
| Athira Pharma (LONA) | 0.3 | $4.8M | 464k | 10.28 |
|
|
| Senti Biosciences Com New (SNTI) | 0.2 | $3.1M | 3.8M | 0.81 |
|
|
| Marker Therapeutics Com New (MRKR) | 0.1 | $2.1M | 1.6M | 1.30 |
|
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.1 | $2.0M | 479k | 4.14 |
|
|
| Gossamer Bio (GOSS) | 0.0 | $329k | -94% | 1.0M | 0.33 |
|
| Imagenebio (IMA) | 0.0 | $250k | 50k | 5.00 |
|
Past Filings by NEA Management Company
SEC 13F filings are viewable for NEA Management Company going back to 2010
- NEA Management Company 2026 Q1 filed May 15, 2026
- NEA Management Company 2025 Q4 filed Feb. 17, 2026
- NEA Management Company 2025 Q3 filed Nov. 14, 2025
- NEA Management Company 2025 Q2 filed Aug. 14, 2025
- NEA Management Company 2025 Q1 filed May 14, 2025
- NEA Management Company 2024 Q4 filed Feb. 14, 2025
- NEA Management Company 2024 Q3 filed Nov. 14, 2024
- NEA Management Company 2024 Q2 filed Aug. 14, 2024
- NEA Management Company 2024 Q1 filed May 15, 2024
- NEA Management Company 2023 Q4 filed Feb. 14, 2024
- NEA Management Company 2023 Q3 filed Nov. 14, 2023
- NEA Management Company 2023 Q2 filed Aug. 11, 2023
- NEA Management Company 2023 Q1 filed May 15, 2023
- NEA Management Company 2022 Q4 filed Feb. 10, 2023
- NEA Management Company 2022 Q3 filed Nov. 14, 2022
- NEA Management Company 2022 Q2 filed Aug. 15, 2022